These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22039528)

  • 1. Picomolar dichotomous activity of gnidimacrin against HIV-1.
    Huang L; Ho P; Yu J; Zhu L; Lee KH; Chen CH
    PLoS One; 2011; 6(10):e26677. PubMed ID: 22039528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Structure-Activity Relationship Correlations of Gnidimacrin Derivatives as Potent HIV-1 Inhibitors and HIV Latency Reversing Agents.
    Liu Q; Cheng YY; Li W; Huang L; Asada Y; Hsieh MT; Morris-Natschke SL; Chen CH; Koike K; Lee KH
    J Med Chem; 2019 Aug; 62(15):6958-6971. PubMed ID: 31343875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C β.
    Lai W; Huang L; Zhu L; Ferrari G; Chan C; Li W; Lee KH; Chen CH
    J Med Chem; 2015 Nov; 58(21):8638-46. PubMed ID: 26509731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daphneodorins A-C, Anti-HIV Gnidimacrin Related Macrocyclic Daphnane Orthoesters from
    Otsuki K; Li W; Asada Y; Chen CH; Lee KH; Koike K
    Org Lett; 2020 Jan; 22(1):11-15. PubMed ID: 31680527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.
    Abreu CM; Price SL; Shirk EN; Cunha RD; Pianowski LF; Clements JE; Tanuri A; Gama L
    PLoS One; 2014; 9(5):e97257. PubMed ID: 24827152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor.
    Huang L; Lai WH; Zhu L; Li W; Wei L; Lee KH; Xie L; Chen CH
    ACS Med Chem Lett; 2018 Mar; 9(3):268-273. PubMed ID: 29541372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel phorbol esters exert dichotomous effects on inhibition of HIV-1 infection and activation of latent HIV-1 expression.
    Zhong Y; Matsuya Y; Nemoto H; Mori M; Saito H; Yamamoto N
    Antivir Chem Chemother; 2005; 16(5):303-13. PubMed ID: 16245646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro.
    Bedoya LM; Márquez N; Martínez N; Gutiérrez-Eisman S; Alvarez A; Calzado MA; Rojas JM; Appendino G; Muñoz E; Alcamí J
    Biochem Pharmacol; 2009 Mar; 77(6):965-78. PubMed ID: 19100719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of daphnane-type diterpene gnidimacrin isolated from Stellera chamaejasme L.
    Yoshida M; Feng W; Saijo N; Ikekawa T
    Int J Cancer; 1996 Apr; 66(2):268-73. PubMed ID: 8603823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of HIV-1 replication in human primary cells by a dolabellane diterpene isolated from the marine algae Dictyota pfaffii.
    Cirne-Santos CC; Teixeira VL; Castello-Branco LR; Frugulhetti IC; Bou-Habib DC
    Planta Med; 2006 Mar; 72(4):295-9. PubMed ID: 16557468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
    Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
    J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests.
    Miyake H; Iizawa Y; Baba M
    J Clin Microbiol; 2003 Jun; 41(6):2515-21. PubMed ID: 12791875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor action of the PKC activator gnidimacrin through cdk2 inhibition.
    Yoshida M; Feng W; Nishio K; Takahashi M; Heike Y; Saijo N; Wakasugi H; Ikekawa T
    Int J Cancer; 2001 Nov; 94(3):348-52. PubMed ID: 11745413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
    Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of PKC betaII in anti-proliferating action of a new antitumor compound gnidimacrin.
    Yoshida M; Heike Y; Ohno S; Ikekawa T; Wakasugi H
    Int J Cancer; 2003 Jul; 105(5):601-6. PubMed ID: 12740906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
    Takashima K; Miyake H; Kanzaki N; Tagawa Y; Wang X; Sugihara Y; Iizawa Y; Baba M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3474-82. PubMed ID: 16048963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
    De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
    Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy.
    Delobel P; Sandres-Sauné K; Cazabat M; Pasquier C; Marchou B; Massip P; Izopet J
    J Acquir Immune Defic Syndr; 2005 Apr; 38(4):382-92. PubMed ID: 15764954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.